Trials / Conditions / Neoplasms Malignant

Neoplasms Malignant

26 registered clinical trials studyying Neoplasms Malignant — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Map of Tumor Genetic Actionability in Argentina NCT06995235	Hospital Italiano de Buenos Aires	—
Recruiting	Prophylactic Mesh Placement During Stoma Closure After Low Anterior Resection NCT05939687	Blokhin's Russian Cancer Research Center	Phase 3
Unknown	Oxygen Atomizing Inhalation of EGCG in the Treatment Interstitial Pneumonia in Cancer Patients NCT05758571	Shandong Cancer Hospital and Institute	Phase 1 / Phase 2
Unknown	A Study of B1962, a PD-L1/VEGF Bispecific Antibody Fusion Protein, for Advanced Solid Tumors NCT05650385	Tasly Biopharmaceuticals Co., Ltd.	Phase 1
Unknown	Clinical Application of Super-resolution Ultrasound(SR-US) Imaging in Solid Tumors NCT06018142	Chinese PLA General Hospital	—
Unknown	Early Clinical Evaluation of 18F-LY3546117 in Tumor Imaging NCT04721756	Avid Radiopharmaceuticals	EARLY_Phase 1
Completed	A Phase 1 Dose Escalation and Expansion Study of AK117 NCT04728334	Akeso	Phase 1
Completed	Improved Adherence With Extended Venous Thromboembolism Prophylaxis After Major Cancer Surgery NCT04479579	McMaster University	Phase 4
Unknown	Clinical Outcomes of NOSES Versus Traditional Robotic-assisted Surgery for Patients With Colorectal Cancer NCT04230772	Taiyuan Li	N/A
Completed	Perceptions, Experiences, and Activity in CancEr Survivors During COVID-19 NCT04637295	University of Nebraska	—
Completed	Existential Distress in Patients with Advanced Cancer and Their Caregivers NCT04600206	Universitätsklinikum Hamburg-Eppendorf	—
Completed	Thromboembolic Risk Screening in Patients With Cancer and COVID-19 NCT04616846	Centre Antoine Lacassagne	N/A
Completed	A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combina NCT04349969	Akesobio Australia Pty Ltd	Phase 1
Completed	A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid Tumors NCT04047290	Akesobio Australia Pty Ltd	Phase 1
Unknown	Cancer Survivors Acute Exercise Response 1 NCT03903848	University of Houston	N/A
Terminated	EPR Tumor Oximetry With CE India Ink NCT03321903	Philip Schaner	—
Terminated	Oxygen Measurements in Subcutaneous Tumors by EPR Oximetry Using OxyChip NCT02706197	Periannan Kuppusamy	N/A
Terminated	Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Po NCT01121588	Pfizer	Phase 1
Terminated	A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies NCT01243762	Merck Sharp & Dohme LLC	Phase 1
Completed	Dose-escalation, Safety, Pharmacokinetics Study of AVE8062 Combined With Bevacizumab in Patients With Advanced NCT01193595	Sanofi	Phase 1
Completed	Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Docetaxel and Cisplatin in Patients NCT01095302	Sanofi	Phase 1
Completed	Effect of Cabazitaxel on the QTc Interval in Cancer Patients NCT01087021	Sanofi	Phase 1
Completed	Dose Escalation, Safety and Pharmacokinetic Study of AVE8062 Combined With Cisplatin in Patients With Solid Tu NCT01021150	Sanofi	Phase 1
Completed	A Study to Investigate the Disposition of Radio-labeled AVE8062 Compound Administered as a 30-minute IV Infusi NCT01063946	Sanofi	Phase 1
Terminated	Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor NCT01001221	Sanofi	Phase 1 / Phase 2
Suspended	Radiofrequency Ablation (RFA) Of Tumors Acquired In Childhood NCT00868647	Seattle Children's Hospital	Phase 2